The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Open accessAbstract
Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-β precursor protein gene (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-β(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3β (aGSK-3β). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused significant reductions in phospho-Tau(Thr 231) and aGSK-3β levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-β, in GSK-3β activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“iPSC-derived neurons from individuals with AD exhibit increased production of Aβ42, active GSK-3β, phosphorylated tau, endosomal abnormalities, and oxidative stress (12–17)”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“but late-stage neuropathological features, such as formation of insoluble tau and neurodegeneration have not been reported.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accumulation of pTau in FAD neurons can be reversed by inhibition of β-secretase, the enzyme that converts APP to β-CTF indicating a direct relationship between APP processing and Tau (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, neuronal endosomal swelling has been classed as an early hallmark of Alzheimer's disease indicative of a perturbation in endosomal cargo sorting [8,9,56].”
From Global identification of neuronal and astrocytic integral membrane proteins that require Retromer for their endosomal recycling (2026) · cites this paper as [56]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, inhibition of γ-secretase (to prevent generation of Aβ from β-CTF) did not reduce pTau, indicating that the effect of APP processing on pTau in early AD neurons is not solely mediated by extracellular Aβ (Israel et al., 2012, Moore et al., 2015).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“pThr231Tau accumulates in APP duplication (APPdp) iPSC-derived FAD neurons (Israel et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Israel et al., 2012
In the citing paper
“Several studies related to neurological disease successfully reverted a disease-associated cellular phenotype in patient-derived cells by correcting the disease-associated mutation, for example in the MAPT gene106,107.”
From CRISPR-based functional genomics for neurological disease (2020) · cites this paper as [106]
In the citing paper
“Multiple groups have characterized iPSC lines from donor cells from FAD and sAD patients, which show increased production of Aβ, particularly Aβ42, and tau hyperphosphorylation in comparison to iPSCs derived from age-matched non-demented controls [66, 82, 101, 175].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
In the citing paper
“Some iPSC lines also have evidence of additional AD-associated pathology such as increased activation of GSK3β [66], increased number of large endosomes [66], and accumulation of intraneuronal Aβ oligomers [82].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [66]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liang, Q., Fujita, R., Yamashita, T., Angulo, S. L., Rhinn, H., Rhee, D. B., Doege, C. A., Chau, L., Aubry, L., Vanti, W. B., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.007 · Cited by 231
RetractedInduction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
Cited by
Sorted by citations
Items 101–200 of 1,002
Sproul, A. A., Jacob, S., Pre, D., Kim, S. H., Nestor, M. W., Navarro-Sobrino, M., Santa-Maria, I., Zimmer, M., Aubry, S., Steele, J. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084547 · Cited by 162
Woodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177
Self-citationMadison, J. M., Zhou, F., Nigam, A., Hussain, A. H., Barker, D., Nehme, R., van der Ven, K., Hsu, J. Y., Wolf, P., Fleishman, M., et al. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.7 · Cited by 177
Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells
Tran, J., Anastacio, H. T. D., & Bardy, C. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-0110-8 · Cited by 190
Self-citationZhang, D., Pekkanen-Mattila, M., Shahsavani, M., Falk, A., Teixeira, A. I., & Herland, A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.028 · Cited by 171
Hibaoui, Y., Grad, I., Letourneau, A., Sailani, M. R., Dahoun, S., Santoni, F. A., Gimelli, S., Guipponi, M., Pelte, M. F., Béna, F., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302848 · Cited by 170
Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer’s disease
Small, S. A., Simoes-Spassov, S., Mayeux, R., & Petsko, G. A. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.08.003 · Cited by 168
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Inhibition of p25/Cdk5 Attenuates Tauopathy in Mouse and iPSC Models of Frontotemporal Dementia
Seo, J., Kritskiy, O., Watson, L. A., Barker, S. J., Dey, D., Raja, W. K., Lin, Y.-T., Ko, T., Cho, S., Penney, J., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.0621-17.2017 · Cited by 156
CRISPR-based functional genomics for neurological disease
Kampmann, M. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0373-z · Cited by 163
Turning back time with emerging rejuvenation strategies
Mahmoudi, S., Xu, L., & Brunet, A. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0206-0 · Cited by 171
Duan, L., Bhattacharyya, B. J., Belmadani, A. A., Pan, L., Miller, R. J., & Kessler, J. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-3 · Cited by 165
Hung, C. O. Y., & Livesey, F. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.095 · Cited by 159
Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 164
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158
Colacurcio, D. J., Pensalfini, A., Jiang, Y., & Nixon, R. A. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.001 · Cited by 167
Chen, H. M., DeLong, C. J., Bame, M., Rajapakse, I., Herron, T. J., McInnis, M. G., & O’Shea, K. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.12 · Cited by 156
How multi-organ microdevices can help foster drug development
Esch, M. B., Smith, A. S. T., Prot, J. M., Oleaga, C., Hickman, J. J., & Shuler, M. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.12.003 · Cited by 156
Chandrasekaran, A., Avci, H. X., Leist, M., Kobolák, J., & Dinnyés, A. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00215 · Cited by 159
Kwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151
Lagomarsino, V. N., Pearse, R. V., Liu, L., Hsieh, Y.-C., Fernandez, M. A., Vinton, E. A., Paull, D., Felsky, D., Tasaki, S., Gaiteri, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.08.003 · Cited by 151
Stem cell therapy for Alzheimer's disease
Liu, X., Yang, L.-P., & Zhao, L. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i8.787 · Cited by 162
Human induced pluripotent stem cells and their use in drug discovery for toxicity testing
Scott, C. W., Peters, M. F., & Dragan, Y. P. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.02.020 · Cited by 157
Sustained synchronized neuronal network activity in a human astrocyte co-culture system
Kuijlaars, J., Oyelami, T., Diels, A., Rohrbacher, J., Versweyveld, S., Meneghello, G., Tuefferd, M., Verstraelen, P., Detrez, J. R., Verschuuren, M., et al. (2016) · Scientific Reports · doi:10.1038/srep36529 · Cited by 153
Arber, C., Toombs, J., Lovejoy, C., Ryan, N. S., Paterson, R. W., Willumsen, N., Gkanatsiou, E., Portelius, E., Blennow, K., Heslegrave, A., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0410-8 · Cited by 148
Recent advances in mesenchymal stem cell membrane-coated nanoparticles for enhanced drug delivery
Wang, M., Xin, Y., Cao, H., Li, W., Hua, Y., Webster, T. J., Zhang, C., Tang, W., & Liu, Z. (2020) · Biomaterials Science · doi:10.1039/d0bm01164a · Cited by 144
Stem cell models of Alzheimer’s disease: progress and challenges
Arber, C., Lovejoy, C., & Wray, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0268-4 · Cited by 143
Modeling Dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons
Jiao, J., Yang, Y., Shi, Y., Chen, J., Gao, R., Fan, Y., Yao, H., Liao, W., Sun, X., & Gao, S. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt275 · Cited by 141
Downregulation of MicroRNA-9 in iPSC-Derived Neurons of FTD/ALS Patients with TDP-43 Mutations
Zhang, Z., Almeida, S., Lu, Y., Nishimura, A. L., Peng, L., Sun, D., Wu, B., Karydas, A. M., Tartaglia, M. C., Fong, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076055 · Cited by 142
Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease
Wadhwani, A. R., Affaneh, A., Van Gulden, S., & Kessler, J. A. (2019) · Annals of Neurology · doi:10.1002/ana.25455 · Cited by 142
Cronin, P., McCarthy, M. J., Lim, A. S. P., Salmon, D. P., Galasko, D. R., Masliah, E., Jager, P. L. D., Bennett, D. A., & Desplats, P. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.10.003 · Cited by 143
Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research
Wray, S., Self, M., Lewis, P. A., Taanman, J., Ryan, N. S., Mahoney, C., Liang, Y., Devine, M. J., Sheerin, U., Houlden, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043099 · Cited by 141
Stem cells: a promising candidate to treat neurological disorders
Zheng, M., Han, H., Song, C., Zhang, Y., Wu, H.-N., Cao, X., Guo, C., & Li, Y. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.235085 · Cited by 139
Tang, X., Zhou, L., Biel, A., Marchetto, M. C., Muotri, A. R., Gage, F. H., & Chen, G. (2013) · Stem Cell Research · doi:10.1016/j.scr.2013.05.002 · Cited by 143
Self-citationAlmeida, S., Zhang, Z., Coppola, G., Mao, W., Futai, K., Karydas, A., Geschwind, M. D., Tartaglia, M. C., Gao, F., Gianni, D., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.09.007 · Cited by 140
Targeted manipulation of the sortilin–progranulin axis rescues progranulin haploinsufficiency
Lee, W. C., Almeida, S., Prudencio, M., Caulfield, T. R., Zhang, Y.-J., Tay, W. M., Bauer, P. O., Chew, J., Sasaguri, H., Jansen-West, K. R., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt534 · Cited by 125
Birnbaum, J. H., Wanner, D., Gietl, A. F., Saake, A., Kündig, T. M., Hock, C., Nitsch, R. M., & Tackenberg, C. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.019 · Cited by 135
Hossini, A. M., Megges, M., Prigione, A., Lichtner, B., Toliat, M. R., Wruck, W., Schröter, F., Nüernberg, P., Kroll, H., Makrantonaki, E., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1262-5 · Cited by 139
Chang, C.-Y., Ting, H.-C., Liu, C.-A., Su, H., Chiou, T., Lin, S., Harn, H., & Ho, T. (2020) · Molecules · doi:10.3390/molecules25082000 · Cited by 140
3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Bhalla, A., Vetanovetz, C. P., Morel, E., Chamoun, Z., Di Paolo, G., & Small, S. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.030 · Cited by 130
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease
Panicker, L. M., Miller, D., Park, T. S., Patel, B., Azevedo, J. L., Awad, O., Masood, M. A., Veenstra, T. D., Goldin, E., Stubblefield, B. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207889109 · Cited by 129
Nanotopography promoted neuronal differentiation of human induced pluripotent stem cells
Song, L., Wang, K., Li, Y., & Yang, Y. S. (2016) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2016.08.041 · Cited by 128
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 136
Treatment of Parkinson’s Disease through Personalized Medicine and Induced Pluripotent Stem Cells
Stoddard-Bennett, T., & Pera, R. A. R. (2019) · Cells · doi:10.3390/cells8010026 · Cited by 137
Nutrition and the ageing brain: Moving towards clinical applications
Flanagan, E. C., Lamport, D. J., Brennan, L., Burnet, P. W. J., Calabrese, V., Cunnane, S. C., de Wilde, M. C., Dye, L., Farrimond, J. A., Lombardo, N. B. E., et al. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101079 · Cited by 132
Prè, D., Nestor, M. W., Sproul, A. A., Jacob, S., Koppensteiner, P., Chinchalongporn, V., Zimmer, M., Yamamoto, A., Noggle, S., & Arancio, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103418 · Cited by 134
Pensalfini, A., Kim, S., Subbanna, S., Bleiwas, C., Goulbourne, C. N., Stavrides, P. H., Jiang, Y., Lee, J., Darji, S., Pawlik, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108420 · Cited by 134
Sabapathy, V., & Kumar, S. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12839 · Cited by 129
Fong, H., Wang, C., Knoferle, J., Walker, D., Balestra, M. E., Tong, L. M., Leung, L., Ring, K. L., Seeley, W. W., Karydas, A., et al. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.08.001 · Cited by 122
Modeling the blood–brain barrier using stem cell sources
Lippmann, E. S., Al-Ahmad, A. J., Palecek, S. P., & Shusta, E. V. (2013) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-10-2 · Cited by 130
iPS cell technologies and cartilage regeneration
Tsumaki, N., Okada, M., & Yamashita, A. (2014) · Bone · doi:10.1016/j.bone.2014.07.011 · Cited by 125
Mahairaki, V., Ryu, J., Peters, A., Chang, Q., Li, T., Park, T. S., Burridge, P. W., Talbot, C. C., Asnaghi, L., Martin, L. J., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0511 · Cited by 120
In vivo modeling of human neuron dynamics and Down syndrome
Real, R., Peter, M., Trabalza, A., Khan, S., Smith, M. A., Dopp, J., Barnes, S. J., Momoh, A., Strano, A., Volpi, E., et al. (2018) · Science · doi:10.1126/science.aau1810 · Cited by 120
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 121
Logan, S., Arzua, T., Canfield, S. G., Seminary, E. R., Sison, S. L., Ebert, A. D., & Bai, X. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180025 · Cited by 143
Deconstructing Mitochondrial Dysfunction in Alzheimer Disease
García‐Escudero, V., Martín-Maestro, P., Perry, G. L., & Ávila, J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/162152 · Cited by 120
Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer’s disease
Marcello, E. E., Saraceno, C., Musardo, S., Vara, H., de la Fuente, A. G., Pelucchi, S., Marino, D. D., Borroni, B., Tramontano, A. L., Pérez‐Otaño, I., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65401 · Cited by 120
Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., & Ikeuchi, T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.348300 · Cited by 124
Kirwan, P., Turner-Bridger, B., Peter, M., Momoh, A., Arambepola, D., Robinson, H. P. C., & Livesey, F. J. (2015) · Development · doi:10.1242/dev.123851 · Cited by 116
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Ganesan, D., & Cai, Q. (2021) · Biochemical Journal · doi:10.1042/bcj20200917 · Cited by 123
Bhat, N. R., & Thirumangalakudi, L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121030 · Cited by 119
Woodruff, G., Reyna, S. M., Dunlap, M., Van Der Kant, R., Callender, J. A., Young, J. E., Roberts, E. A., & Goldstein, L. S. B. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.034 · Cited by 105
Self-citationPovero, D., Pinatel, E., Leszczynska, A., Goyal, N. P., Nishio, T., Kim, J., Kneiber, D. B., Horcel, L. D. A., Eguchi, A., Ordonez, M. P., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.125652 · Cited by 114
Di, J., Cohen, L. S., Corbo, C. P., Phillips, G. R., Idrissi, A. E., & Alonso, A. D. C. (2016) · Scientific Reports · doi:10.1038/srep20833 · Cited by 120
Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease
Jorfi, M., D’Avanzo, C., Tanzi, R. E., Kim, D. Y., & Irimia, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-20436-8 · Cited by 112
Alzheimer's in 3D culture: Challenges and perspectives
D'Avanzo, C., Aronson, J., Kim, Y. H., Choi, S. H., Tanzi, R. E., & Kim, D. Y. (2015) · BioEssays · doi:10.1002/bies.201500063 · Cited by 111
Xu, X., Lei, Y., Luo, J., Wang, J., Zhang, S., Yang, X., Sun, M., Nuwaysir, E. F., Fan, G.-H., Zhao, J. Y., et al. (2012) · Stem Cell Research · doi:10.1016/j.scr.2012.11.005 · Cited by 115
Thinking out of the dish: what to learn about cortical development using pluripotent stem cells
van den Ameele, J., Tiberi, L., Vanderhaeghen, P., & Espuny-Camacho, I. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2014.03.005 · Cited by 110
Human-induced pluripotent stem cells: potential for neurodegenerative diseases
Ross, C. A., & Akimov, S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu204 · Cited by 111
Young, J. E., Fong, L. K., Frankowski, H., Petsko, G. A., Small, S. A., & Goldstein, L. S. B. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.01.031 · Cited by 110
Self-citationModeling human neurological disorders with induced pluripotent stem cells
Imaizumi, Y., & Okano, H. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12625 · Cited by 111
Handel, A. E., Chintawar, S., Lalic, T., Whiteley, E. S., Vowles, J., Giustacchini, A., Argoud, K., Sopp, P., Nakanishi, M., Bowden, R. J., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv637 · Cited by 108
Modeling and Targeting Alzheimer’s Disease With Organoids
Papaspyropoulos, A., Tsolaki, M., Foroglou, N., & Pantazaki, Α. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00396 · Cited by 107
Alzheimer's disease-related amyloid-β induces synaptotoxicity in human iPS cell-derived neurons
Nieweg, K., Andreyeva, A., van Stegen, B., Tanriöver, G., & Gottmann, K. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.72 · Cited by 105
Wu, C., Lien, C., Hou, W., Chiang, P., & Tsai, K. (2016) · Scientific Reports · doi:10.1038/srep27358 · Cited by 106
Three‐Dimensional Models of the Human Brain Development and Diseases
Jorfi, M., D’Avanzo, C., Kim, D. Y., & Irimia, D. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700723 · Cited by 106
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelová, P., Růžička, J., Urdzíková, L. M., & Syková, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 110
Significance of epigenetics for understanding brain development, brain evolution and behaviour
Keverne, E. B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.030 · Cited by 104
Barák, M., Fedorová, V., Pospíšilová, V., Raška, J., Vochyánová, S., Sedmík, J., Hříbková, H., Klímová, H., Váňová, T., & Bohačiaková, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10254-3 · Cited by 102
Ercan-Herbst, E., Ehrig, J., Schöndorf, D. C., Behrendt, A., Klaus, B., Gomez Ramos, B., Prat Oriol, N., Weber, C., & Ehrnhoefer, D. E. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0823-2 · Cited by 101
Cossec, J., Lavaur, J., Berman, D. E., Rivals, I., Hoischen, A., Stora, S., Ripoll, C., Mircher, C., Grattau, Y., Olivo‐Marín, J., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds142 · Cited by 106
Imaizumi, K., Sone, T., Ibata, K., Fujimori, K., Yuzaki, M., Akamatsu, W., & Okano, H. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.005 · Cited by 101
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Young‐Pearse, T. L., Lee, H., Hsieh, Y., Chou, V., & Selkoe, D. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.005 · Cited by 104
Guix, F. X., Sannerud, R., Berditchevski, F., Arranz, A. M., Horré, K., Snellinx, A., Thathiah, A., Saido, T. C., Saito, T., Rajesh, S., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0165-0 · Cited by 103
Jiang, Y., Rigoglioso, A., Peterhoff, C. M., Pawlik, M., Sato, Y., Bleiwas, C., Stavrides, P., Smiley, J. F., Ginsberg, S. D., Mathews, P. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.013 · Cited by 97
Accelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M. S., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 98
Synaptogenic effect of APP -Swedish mutation in familial Alzheimer’s disease
Zhou, B., Lu, J. G., Siddu, A., Wernig, M., & Südhof, T. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9380 · Cited by 99
Hung, C., Tuck, E., Stubbs, V., van der Lee, S. J., Aalfs, C., van Spaendonk, R., Scheltens, P., Hardy, J., Holstege, H., & Livesey, F. J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109259 · Cited by 98
Pomeshchik, Y., Klementieva, O., Gil, J., Martinsson, I., Hansen, M. G., de Vries, T., Sancho-Balsells, A., Russ, K., Savchenko, E., Collin, A., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.06.001 · Cited by 95
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 96
Neural Stem Cells and Methods for Their Generation From Induced Pluripotent Stem Cells in vitro
Galiakberova, A. A., & Dashinimaev, E. B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00815 · Cited by 100
GSK3: A potential target and pending issues for treatment of Alzheimer's disease
Zhao, J., Wei, M., Guo, M., Wang, M., Niu, H., Xu, T., & Zhou, Y. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14818 · Cited by 108
Stuck in traffic: an emerging theme in diseases of the nervous system
Neefjes, J., & van der Kant, R. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.11.006 · Cited by 98
Pavoni, S., Jarray, R., Nassor, F., Guyot, A.-C., Cottin, S., Rontard, J., Mikol, J., Mabondzo, A., Deslys, J.-P., & Yates, F. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209150 · Cited by 97
The Retromer Complex and Sorting Nexins in Neurodegenerative Diseases
Zhang, H., Huang, T. Y., Hong, Y., Yang, W., Zhang, X., Luo, H., Xu, H., & Wang, X. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00079 · Cited by 92
Vazin, T., Ball, K. A., Lü, H., Park, H., Ataeijannati, Y., Head-Gordon, T. L., Poo, M., & Schaffer, D. V. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.005 · Cited by 94
Deng, J., Habib, A., Obregon, D. F., Barger, S. W., Giunta, B. N., Wang, Y., Hou, H., Sawmiller, D. R., & Tan, J. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13351 · Cited by 91
Two decades of embryonic stem cells: a historical overview
Eguizábal, C., Arán, B., Lopes, S. M. C. D. S., Geens, M., Heindryckx, B., Panula, S., Popovic, M., Vassena, R., & Veiga, A. (2018) · Human Reproduction Open · doi:10.1093/hropen/hoy024 · Cited by 97
Metadata
- Authors
- Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., Carson, C. T., Laurent, L. C., Marsala, M., Gage, F. H., Remes, A. M., Koo, E. H., & Goldstein, L. S. B.
- Affiliations
- Howard Hughes Medical Institute (US)
- Salk Institute for Biological Studies (US)
- University of California San Diego (US)
- Scripps Research Institute (US)
- BD Biosciences (United States) (US)
- University of Oulu (FI)
- Corresponding author
- Goldstein, Lawrence S. B.
- ORCID
- Venue
- Nature
- Published
- 2012-01-25
- Volume
- 482
- Issue
- 7384
- Pages
- 216-220
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3338985
- OpenAlex
- W2088714934
- Cited by
- 1,253
- References
- 37
- Citations by year
- 2026: 45 · 2025: 55 · 2024: 73 · 2023: 61 · 2022: 100 · 2021: 73 · 2020: 105 · 2019: 86 · 2018: 87 · 2017: 76 · 2016: 108 · 2015: 105 · 2014: 106 · 2013: 95 · 2012: 74
- FWCI
- 81.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- (No Title)
- Funders
- Howard Hughes Medical Institute
- National Institute on Aging (P50AG005131)
- National Institute of General Medical Sciences (T32GM008666)
- National Institute of Neurological Disorders and Stroke (P30NS047101, RC1NS068705)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD001259)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, induced pluripotent stem cells, familial Alzheimer's disease, sporadic Alzheimer's disease, amyloid-beta secretion, gamma-secretase inhibitors, beta-secretase inhibitors, phosphorylated tau, glycogen synthase kinase-3β, APP proteolytic processing, iPSC-derived neurons, patient-derived fibroblasts
- MeSH terms
- Aged, 80 and over, Alzheimer Disease, Astrocytes, Cells, Cultured, Enzyme Activation, Female, Fibroblasts, Humans, Male, Middle Aged, Models, Biological, Neurons, Peptide Fragments, Phosphoproteins, Phosphorylation, Protease Inhibitors, Endosomes, Biomarkers, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Synapsins, tau Proteins, Coculture Techniques, Glycogen Synthase Kinase 3, Amyloid Precursor Protein Secretases, Induced Pluripotent Stem Cells, Proteolysis, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
